COVID-19 medicine: Lupin launches Favipiravir in India at Rs 49 per tablet
.jpg)
Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use.
Lupin's Covihalt dosage strength has been developed keeping in mind the convenience of administration. It is available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs 49 per tablet.
"COVID-19 is a global pandemic and in India we are seeing a surge in the number of cases on a daily basis," said Rajeev Sibal, President of India region formulations at Lupin Ltd.
"In these tough times, it is our duty to support the nation in fighting this pandemic and ensuring affordable drugs are made available for impacted patients," he said adding that Covihalt is a vital step in this direction.
A day earlier, Sun Pharmaceutical Industries launched Favipiravir (200 mg) at a price of Rs 35 per tablet.
Lupin has 15 manufacturing sites, 7 research centres and more than 20,000 professionals working globally.
The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and active pharma ingredients in over 100 markets in the United States, India, South Africa and across the Asia Pacific, Latin America, Europe and Middle East regions.
Other Latest News
.webp)
Cement maker ACC on Thursday said its profit after tax (PAT) increased four-fold to Rs 945 crore in the March quarter of the previous fiscal year on account of robust sales.
The company had reported a PAT of Rs 236 crore in the year-ago period.
Revenue from operations rose to Rs 5,409 crore in the fourth quarter as compared with Rs 4,791 crore in the year-ago period, ACC Ltd said in a regulatory filing.
.webp)
Nestle on Thursday missed first-quarter organic sales growth estimates, as the world's biggest packaged food company hiked prices and sold fewer products, particularly in North America.
The maker of Maggi noodles, Nescafe coffee and KitKat chocolate wafer bars confirmed its 2024 guidance of organic sales growth of about 4 per cent and a moderate increase in underlying trading profit margin.
.webp)
Shares of Hitachi Energy were buzzing in trade on Thursday as they soared as much as 18.89 per cent to hit a fresh record high of Rs 9,765.30 per share, driven by expansion plans. On the other hand, S&P BSE 500 was trading 0.21 per cent higher at 74,010.29 levels, as of 1:02 PM.
Hitachi Energy intends to establish additional global capability centres (GCCs) in India to bolster its local operations in response to escalating energy demand and the government's focus on expanding renewable energy generation, according to Reuters.
.webp)
Air India Express will give first-time voters aged 18 to 22 a 19 per cent discount on domestic and international flight tickets for travelling to their home constituencies and back, the Economic Times (ET) reported.
This deal is part of the airline’s "#VoteAsYouAre" campaign, “designed to mobilise first-time voters to fly home to exercise their constitutional right and help guide the flight path of the nation", ET reported.
.webp)
National Stock Exchange (NSE) on Wednesday introduced derivative contracts on Nifty Next 50 index, which received a positive response from market participants.
More than 375 trading members from across the country participated in the index derivatives, the National Stock Exchange (NSE) said in a statement.
.webp)
.webp)
.webp)
.webp)
.webp)
